BGI Group has noted that the 2026 U.S. National Defense Authorization Act contains provisions that would restrict certain Chinese biotechnology companies from conducting business in the United States. Such restrictions could limit U.S. entities’ ability to choose business and research partners and lead to higher healthcare costs and reduced access to advanced life-science technologies.

These provisions, previously introduced as the ‘Biosecure Act’, risk stifling competition and favoring existing American biotech companies. Public lobbying disclosure records show that one large U.S. biotech company has actively lobbied on both the National Defense Authorization Act and the Biosecure Act since similar language was first proposed in 2023.

BGI Group, a privately owned global life-science organization, fully supports the protection of personal privacy and data security. BGI does not serve patients in the United States and does not have access to Americans’ genetic data. Allegations that BGI collects Americans’ DNA data or poses risks to U.S. national security are unfounded. All of BGI’s global services and research are conducted for civilian and scientific purposes only, in compliance with applicable laws and regulations and guided by rigorous data protection standards.

As a global leader in life sciences, BGI Group will continue to advocate for the open sharing of scientific tools and discoveries to combat diseases and improve human health worldwide.

Related statements by BGI Group on Biosecure Act:

https://en.genomics.cn/news-6880.html

https://en.genomics.cn/news-6935.html